Complete financial analysis of Arcus Biosciences, Inc. (RCUS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcus Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Hangzhou Landscaping Incorporated (605303.SS) Income Statement Analysis – Financial Results
- Aspyra Inc. (APYI) Income Statement Analysis – Financial Results
- Vintage Securities Limited (VINTAGES.BO) Income Statement Analysis – Financial Results
- Platt Nera International Limited (1949.HK) Income Statement Analysis – Financial Results
- Thai Union Group Public Company Limited (TU-R.BK) Income Statement Analysis – Financial Results
Arcus Biosciences, Inc. (RCUS)
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 117.00M | 112.00M | 382.88M | 77.52M | 15.00M | 8.35M | 1.41M | 0.00 |
| Cost of Revenue | 340.00M | 14.00M | 7.06M | 159.00M | 78.48M | 49.65M | 2.61M | 1.31M |
| Gross Profit | -223.00M | 98.00M | 375.83M | -81.48M | -63.48M | -41.29M | -1.20M | -1.31M |
| Gross Profit Ratio | -190.60% | 87.50% | 98.16% | -105.12% | -423.21% | -494.35% | -84.85% | 0.00% |
| Research & Development | 340.00M | 288.00M | 256.35M | 159.35M | 78.48M | 49.65M | 47.22M | 14.25M |
| General & Administrative | 117.00M | 104.00M | 72.29M | 42.40M | 25.23M | 13.57M | 7.64M | 3.94M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 117.00M | 104.00M | 72.29M | 42.40M | 25.23M | 13.57M | 7.64M | 3.94M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 457.00M | 392.00M | 328.63M | 201.75M | 103.71M | 63.21M | 54.85M | 18.18M |
| Cost & Expenses | 457.00M | 392.00M | 328.63M | 201.75M | 103.71M | 63.21M | 54.85M | 18.18M |
| Interest Income | 41.00M | 16.00M | 657.00K | 1.38M | 5.20M | 4.92M | 359.00K | 212.00K |
| Interest Expense | 2.00M | 2.00M | 260.00K | 0.00 | 0.00 | 4.92M | 0.00 | 0.00 |
| Depreciation & Amortization | 8.00M | 14.00M | 7.06M | 4.39M | 3.58M | 3.66M | 2.61M | 1.31M |
| EBITDA | -283.00M | -250.00M | 61.96M | -118.47M | -81.13M | -51.20M | -50.83M | -16.87M |
| EBITDA Ratio | -241.88% | -235.71% | 14.34% | -161.06% | -591.39% | -671.47% | -3,597.24% | 0.00% |
| Operating Income | -340.00M | -280.00M | 54.25M | -124.24M | -88.71M | -54.86M | -53.44M | -18.18M |
| Operating Income Ratio | -290.60% | -250.00% | 14.17% | -160.27% | -591.39% | -656.76% | -3,782.09% | 0.00% |
| Total Other Income/Expenses | 39.00M | 14.00M | 397.00K | 1.38M | 4.00M | 5.27M | 359.00K | 212.00K |
| Income Before Tax | -301.00M | -266.00M | 54.65M | -122.86M | -84.71M | -49.59M | -53.08M | -17.97M |
| Income Before Tax Ratio | -257.26% | -237.50% | 14.27% | -158.49% | -564.73% | -593.73% | -3,756.69% | 0.00% |
| Income Tax Expense | 6.00M | 1.00M | 1.82M | -6.18M | -8.78M | 5.27M | 0.00 | 0.00 |
| Net Income | -307.00M | -267.00M | 53.00M | -116.68M | -75.93M | -49.59M | -53.08M | -17.97M |
| Net Income Ratio | -262.39% | -238.39% | 13.84% | -150.52% | -506.21% | -593.73% | -3,756.69% | 0.00% |
| EPS | -4.15 | -3.71 | 0.76 | -2.13 | -1.73 | -1.43 | -1.25 | -0.73 |
| EPS Diluted | -4.15 | -3.71 | 0.71 | -2.13 | -1.73 | -1.43 | -1.25 | -0.73 |
| Weighted Avg Shares Out | 74.00M | 72.00M | 69.35M | 54.79M | 43.83M | 34.62M | 42.55M | 24.55M |
| Weighted Avg Shares Out (Dil) | 74.00M | 72.00M | 73.97M | 54.79M | 43.83M | 34.62M | 42.55M | 24.55M |
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
Arcus Biosciences Announces New Employment Inducement Grants
First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer
Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
Source: https://incomestatements.info
Category: Stock Reports